Low-dose aspirin: effective cancer chemoprevention in Lynch syndrome

Kevin J Monahan

Open source

DOI
10.1016/s2468-1253(26)00124-x
Published
2026-09
Container
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s2468-1253-26-00124-x,
  title = {Low-dose aspirin: effective cancer chemoprevention in Lynch syndrome},
  author = {Kevin J Monahan},
  year = {2026},
  journal = {The Lancet Gastroenterology \& Hepatology},
  doi = {10.1016/s2468-1253(26)00124-x},
  url = {https://doi.org/10.1016/s2468-1253(26)00124-x}
}

RIS

TY  - JOUR
TI  - Low-dose aspirin: effective cancer chemoprevention in Lynch syndrome
AU  - Kevin J Monahan
PY  - 2026
JO  - The Lancet Gastroenterology & Hepatology
DO  - 10.1016/s2468-1253(26)00124-x
UR  - https://doi.org/10.1016/s2468-1253(26)00124-x
ER  - 

APA

Monahan, K. J. (2026). Low-dose aspirin: effective cancer chemoprevention in Lynch syndrome. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(26)00124-x

Source records